Insight on Novartis’s first-of-its-kind not-for-profit medicine portfolio for symptomatic treatment of COVID-19
Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major... Read More
Market Exclusivity Case Study: XIFAXAN (rifaximin)
Posted on07 May 2020
Comments0
Bausch Health Companies Inc. along with its wholly owned subsidiary, Salix Pharmaceuticals, which is one of the largest specialty pharmaceutical companies in... Read More
Sandoz to commercialize proposed multiple sclerosis biosimilar natalizumab
Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a... Read More
Sandoz licensing agreement with EirGenix to commercialize trastuzumab biosimilar
Posted on02 May 2019
TagsBiosimilar, biosimilar deals, biosimilar of sandoz, drug licensing, EirGenix, sandoz, trastuzumab
Comments0
Sandoz, a Novartis division and a global leader in biosimilars, has entered into an agreement to commercialize a proposed trastuzumab biosimilar. This... Read More
Sandoz introduces Symjepi 0.3 mg injection in US market to treat allergic reactions
Sandoz Inc, a Novartis division, announced the US market introduction of Symjepi (epinephrine) 0.3 mg injection for the emergency treatment of allergic... Read More
AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Posted on17 Dec 2018
TagsAbbVie, Amgen, biosimilar of sandoz, Boehringer Ingelheim, Fresenius Kabi, humira, Merck, Momenta, Mylan, novartis, Novartis’ Sandoz, Samsung Bioepis, sandoz
Comments0
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting... Read More
Adalimumab Biosimilar Litigation: Sandoz’s settlement with AbbVie
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with... Read More
Hyrimoz Sandoz’s biosimilar got European marketing approval
Posted on31 Jul 2018
Comments0
Sandoz, a Novartis division and the pioneer and global leader in biosimilars, has announced that the European Commission (EC) granted marketing authorization... Read More
Case Study: Sandoz’s EU approval for Rixathon
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, has announced that the European Commission (EC) has approved Rixathon... Read More
Novartis’ Sandoz Buys European Rights to Biosimilar Remicade
Novartis’ Sandoz unit has acquired from Pfizer rights to develop and commercialize a biosimilar to Remicade® (infliximab) in the 28-nation European Economic... Read More